*ST Mingde has responded to its plan to acquire a 100% stake in Wuhan Bicare for 190 million yuan, stating the move is based on long-term strategic considerations aimed at enhancing the company's comprehensive competitiveness and sustained profitability. The company announced on June 30 that it intends to purchase all of Bicare's equity held by Blue Sail Medical with cash, a transaction that constitutes a major asset restructuring. Blue Sail Medical has committed that Bicare's cumulative net profit from 2026 to 2028 will be no less than 65 million yuan. *ST Mingde was previously placed under delisting risk warning after its 2025 financial data triggered the relevant indicators. The company stated that after the acquisition, total assets, operating revenue, net profit attributable to the parent company, and basic earnings per share will all increase, helping to improve its financial position. The appraisal agency, using December 31, 2025 as the base date, applied the income approach and arrived at an appraised value of 190.6 million yuan for all of Bicare's shareholders' equity, a 59.62% premium over the book value of 119 million yuan. Chairwoman Chen Lili said the acquisition will allow the company to enter the industrial emergency rescue and supermarket sectors, broaden overseas channels, build a coordinated ecosystem of diagnosis, protection, and treatment, and inject high-quality assets to strengthen sustained profitability.
Blue Sail Medical Co LtdBlue Sail Medical sells Bicare for 190 million yuan with a profit guarantee, generating cash inflow and reducing risk.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class ABicare is acquired at a premium valuation with a profit guarantee, providing a clear exit for its shareholders.